Drugs / Felzartamab
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06285201 | Mar → Aug 2024 | — | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06064929 | Nov 2023 → Jun 2026 | lupus nephritis | HI-Bio, A Biogen Company | Completed | No outcome recorded |
| Phase 1 | NCT05140824 | Dec 2021 → Dec 2022 | systemic lupus erythematosus | TJ Biopharma Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04145440 | Oct 2019 → Jan 2022 | autoimmune disease, membranous glomerulonephritis | HI-Bio, A Biogen Company | Completed | No outcome recorded |
| Phase 1/2 | NCT01421186 | Jul 2011 → Aug 2020 | plasma cell myeloma | MorphoSys AG | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07219043 | Jan 2026 → Feb 2028 expected | vasculitis | Biogen | Recruiting | No outcome recorded |
| Phase 2 | NCT04893096 | Oct 2021 → Feb 2025 | membranous glomerulonephritis | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 2 | NCT05065970 | Aug 2021 → Feb 2023 | IgA glomerulonephritis | HI-Bio, A Biogen Company | Completed | No outcome recorded |
| Phase 2 | NCT04733040 | Jan 2021 → Dec 2023 | membranous glomerulonephritis | HI-Bio, A Biogen Company | Completed | No outcome recorded |
| Phase 2 | NCT03860038 | Jan 2019 → Jan 2023 | plasma cell myeloma | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07444489 | Apr 2026 → May 2031 expected | transplant rejection, vasculitis | Biogen | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06962800 | May 2025 → Dec 2028 expected | idiopathic membranous glomerulonephritis | Biogen | Recruiting | No outcome recorded |
| Phase 3 | NCT06935357 | May 2025 → May 2027 expected | IgA glomerulonephritis | Biogen | Recruiting | No outcome recorded |
| Phase 3 | NCT06685757 | Dec 2024 → Dec 2026 expected | transplant rejection | Biogen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03952091 | Mar 2019 → Jun 2024 | plasma cell myeloma | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05021484 Comparator | Oct 2021 → Mar 2024 | transplant rejection | Farsad Eskandary | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Felzartamab | “Study of Felzartamab in Healthy Adult Subjects” NCT06285201 ↗ |
| Known as | MOR03087 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01421186 ↗ |
| Known as | MOR202 | “the human anti-CD38 antibody MOR03087 (MOR202)” NCT01421186 ↗ |
| Known as | TJ202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03952091 ↗ |
| Action | Deplete | “Antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis are the principal mechanisms of action for MOR202-induced lysis of myeloma cells.” NCT04893096 ↗ |
| Modality | Monoclonal antibody | “MOR202 is a fully human recombinant monoclonal antibody against CD38” NCT04893096 ↗ |
| Route | Intravenous | “patients will receive a biweekly intravenous infusion of MOR03087” NCT01421186 ↗ |
| Target | CD38 | “human anti-CD38 antibody MOR202” NCT04145440 ↗ |